These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Juloori A; Katipally RR; Lemons JM; Singh AK; Iyer R; Robbins JR; George B; Hall WA; Pitroda SP; Arif F; Fung J; Pillai A; Liao CY; Sharma M; Liauw SL Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):202-213. PubMed ID: 36108891 [TBL] [Abstract][Full Text] [Related]
10. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336 [TBL] [Abstract][Full Text] [Related]
11. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992 [TBL] [Abstract][Full Text] [Related]
12. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646 [TBL] [Abstract][Full Text] [Related]
13. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity. Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225 [TBL] [Abstract][Full Text] [Related]
14. Quality of life and patient-reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy. Hoogland AI; Brohl AS; Small BJ; Michael L; Wuthrick E; Eroglu Z; Blakaj D; Verschraegen C; Khushalani NI; Jim HSL; Kim S Cancer Med; 2024 Jul; 13(14):e7464. PubMed ID: 39021272 [TBL] [Abstract][Full Text] [Related]
15. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. Hellmann MD; Paz-Ares L; Bernabe Caro R; Zurawski B; Kim SW; Carcereny Costa E; Park K; Alexandru A; Lupinacci L; de la Mora Jimenez E; Sakai H; Albert I; Vergnenegre A; Peters S; Syrigos K; Barlesi F; Reck M; Borghaei H; Brahmer JR; O'Byrne KJ; Geese WJ; Bhagavatheeswaran P; Rabindran SK; Kasinathan RS; Nathan FE; Ramalingam SS N Engl J Med; 2019 Nov; 381(21):2020-2031. PubMed ID: 31562796 [TBL] [Abstract][Full Text] [Related]
16. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. Tawbi HA; Forsyth PA; Algazi A; Hamid O; Hodi FS; Moschos SJ; Khushalani NI; Lewis K; Lao CD; Postow MA; Atkins MB; Ernstoff MS; Reardon DA; Puzanov I; Kudchadkar RR; Thomas RP; Tarhini A; Pavlick AC; Jiang J; Avila A; Demelo S; Margolin K N Engl J Med; 2018 Aug; 379(8):722-730. PubMed ID: 30134131 [TBL] [Abstract][Full Text] [Related]
17. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM; Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204 [TBL] [Abstract][Full Text] [Related]
18. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. Klein O; Kee D; Nagrial A; Markman B; Underhill C; Michael M; Jackett L; Lum C; Behren A; Palmer J; Tebbutt NC; Carlino MS; Cebon J JAMA Oncol; 2020 Sep; 6(9):1405-1409. PubMed ID: 32729929 [TBL] [Abstract][Full Text] [Related]
20. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]